Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host.

Slides:

Advertisements

Similar presentations

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Advertisements

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Biology of Blood and Marrow Transplantation

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and.

Sabina Kersting, Leo F. Verdonck

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Mammalian Target of Rapamycin Inhibitor–Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Nienke M. G. Rorije, Margaret M. Shea, Gowri Satyanarayana, Sarah P

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients Nicolas.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Merve Postalcioglu, Haesook T. Kim, Faruk Obut, Benjamin C

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

What is quality in a transplant program?

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Karen K. Ballen, Thomas R. Spitzer, Beow Y

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Sarah Nikiforow, Haesook T

Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation Philippe Armand, Haesook T. Kim, Joanna Rhodes,

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation Lindsey E.

Presentation transcript:

Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens Corey Cutler, Shuli Li, Haesook T. Kim, Patricia Laglenne, Kwok Chuen Szeto, Laura Hoffmeister, M. Joel Harrison, Vincent Ho, Edwin Alyea, Stephanie J. Lee, Robert Soiffer, Stephen Sonis, Joseph H. Antin Biology of Blood and Marrow Transplantation Volume 11, Issue 5, Pages 383-388 (May 2005) DOI: 10.1016/j.bbmt.2005.02.006 Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Mucositis incidence and duration. A, Peak mucositis scores were significantly lower in the ST group. B, Boxplot demonstrating differences in mucositis duration. The limits of the box represent the 25th and 75th percentiles for the group, the solid line in the center of the box represents the median for the group, and the tails arising out of the box represents the range that includes 95% of observed values. Duration of mucositis ≥2 was also significantly shorter. A mucositis score of 0 connotes normal oral mucosa; 1 indicates the presence of erythema only; 2 and 3 reflect the presence of ulceration of 1 or 2 sites, respectively (slight to moderate mucositis); and 4 (3 ulcerative sites) or 5 (>3 sites of ulceration) is consistent with severe mucositis. Biology of Blood and Marrow Transplantation 2005 11, 383-388DOI: (10.1016/j.bbmt.2005.02.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Narcotic use. Patients in the ST group received narcotics on fewer days after transplantation (P = .08). There was a trend to decreased total milligrams of morphine equivalents (MME) used after transplantation. When standardized to posttransplantation days or posttransplantation days when any narcotic was administered, the trend to fewer MME remained. NS indicates not significant. Biology of Blood and Marrow Transplantation 2005 11, 383-388DOI: (10.1016/j.bbmt.2005.02.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 TPN use and duration of use. A, Less TPN was used in the ST group (P = .08). B, The duration of TPN use was significantly shorter in the ST group (P = .005). Biology of Blood and Marrow Transplantation 2005 11, 383-388DOI: (10.1016/j.bbmt.2005.02.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Duration of hospitalization: the hospitalization duration was 4 days shorter from the time of transplantation in the ST group. Biology of Blood and Marrow Transplantation 2005 11, 383-388DOI: (10.1016/j.bbmt.2005.02.006) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions